<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00547456</url>
  </required_header>
  <id_info>
    <org_study_id>05.02.097</org_study_id>
    <nct_id>NCT00547456</nct_id>
  </id_info>
  <brief_title>Consequences of Nocturnal and Daytime Hypoxemia in COPD</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will determine whether oxygen therapy lowers the level of substances in the blood which
      cause inflammation, which is one of the adverse effects of COPD and whether oxygen improves
      overall well being and quality of life as well as sleep quality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Isolated nocturnal hypoxemia contributes to chronic systemic inflammation in COPD
      by activating circulating neutrophils.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstration of Improvement in Systemic Inflammation, Sleep Quality and Health Related Quality of Life With Nocturnal Oxygen Supplementation.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Decrease in oxygen level when sleeping</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are their own controls and tested pre and post the addition of night time supplemental oxygen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>Oxygen 2-3L Nasal cannula</description>
    <arm_group_label>Decrease in oxygen level when sleeping</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males or females with a diagnosis of COPD screened for nocturnal desaturation as
             indicated above.

          -  Clinical stability defined by absence of treatment change or need for acute care
             within the last two months.

          -  Weight stable, within 5%, in the previous three months as measured during office
             visits.

          -  Willingness to participate in a clinical study.

        Exclusion Criteria:

          -  Acute illness within the preceding 2 months.

          -  Patients who received systemic glucocorticoid therapy within the past month.

          -  Clinical and/or overnight pulse oximetry evidence of obstructive sleep apnea (OSA).
             The Multivariate Apnea Prediction Questionnaire (MAP) will be given to all patients to
             assess the likelihood of OSA based on common symptoms of this disorder. While we
             recognize that this screening instrument was not evaluated specifically in COPD
             patients, it assesses common signs and symptoms of OSA. This tool has been shown to
             identify OSA with 95% sensitivity (63). In addition, the ODI 4% will be determined
             from the overnight pulse oximetry recording. Patients will be excluded if the MAP
             score is &gt; 0.4 or if the ODI 4% is &gt;15/hour, which is suggestive of the concomitant
             presence of obstructive sleep apnea.

          -  Hypercapnia defined as PaCO2 &gt; 50 mmHg on resting arterial blood gas

          -  Previous diagnosis of erythrocytosis, pulmonary vascular disease, pleural effusions,
             ischemic heart disease or congestive heart failure.

          -  No chronic illnesses known to affect the inflammatory response such as infection,
             collagen vascular disease, liver disease, thyroid disease or diabetes.

          -  Primary care or pulmonary physician refusal.

          -  Patient refusal for any reason.

          -  Lack of capacity to participate in the informed consent process.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rubin Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Shore LIJ Health System</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2007</study_first_submitted>
  <study_first_submitted_qc>October 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2007</study_first_posted>
  <results_first_submitted>May 27, 2015</results_first_submitted>
  <results_first_submitted_qc>November 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2015</results_first_posted>
  <last_update_submitted>November 13, 2015</last_update_submitted>
  <last_update_submitted_qc>November 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>recruitment details occurred as outlined in protocol</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Decrease in Oxygen Level When Sleeping</title>
          <description>Patients are their own controls and tested pre and post the addition of night time supplemental oxygen
Oxygen: Oxygen 2-3L Nasal cannula</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Decrease in Oxygen Level When Sleeping</title>
          <description>Patients are their own controls and tested pre and post the addition of night time supplemental oxygen
Oxygen: Oxygen 2-3L Nasal cannula</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>participants between the ages of 18-65</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="40" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>nocturnal hypoxemia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants with Nocturnal and Daytime Hypoxemia in COPD</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Demonstration of Improvement in Systemic Inflammation, Sleep Quality and Health Related Quality of Life With Nocturnal Oxygen Supplementation.</title>
        <time_frame>4 weeks</time_frame>
        <population>The assay used did not work, as a result, no data for any Outcome Measures was collected. The trial is closed and completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Decrease in Oxygen Level When Sleeping</title>
            <description>Patients are their own controls and tested pre and post the addition of night time supplemental oxygen
Oxygen: Oxygen 2-3L Nasal cannula</description>
          </group>
        </group_list>
        <measure>
          <title>Demonstration of Improvement in Systemic Inflammation, Sleep Quality and Health Related Quality of Life With Nocturnal Oxygen Supplementation.</title>
          <population>The assay used did not work, as a result, no data for any Outcome Measures was collected. The trial is closed and completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Decrease in Oxygen Level When Sleeping</title>
          <description>Patients are their own controls and tested pre and post the addition of night time supplemental oxygen
Oxygen: Oxygen 2-3L Nasal cannula</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rubin Cohen, MD</name_or_title>
      <organization>North Shore LIJ Health System</organization>
      <phone>516-465-5400</phone>
      <email>rocohen@nshs.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

